Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS · Delayed Price · Currency is USD
37.80
-1.40 (-3.57%)
Feb 17, 2026, 9:30 AM EST
TKPHF Revenue
Takeda Pharmaceutical Company had revenue of 1.19T JPY in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to 4.52T, down -5.56% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.52T JPY
Revenue Growth
-5.56%
P/S Ratio
2.10
Revenue / Employee
95.20M JPY
Employees
47,455
Market Cap
59.74B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.68B | 8.65% |
| Mar 31, 2013 | 1.56T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 34.87M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
Takeda Pharmaceutical Company News
- 8 days ago - Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Benzinga
- 8 days ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 9 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 9 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 9 days ago - Takeda deepens AI drug discovery push with $1.7 billion Iambic deal - Reuters
- 9 days ago - Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules - Business Wire
- 13 days ago - Japanese drugmakers slump after Trump unveils discount drug website - Reuters
- 15 days ago - Q3 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript - GuruFocus